Watch China Medical & HealthCare Group Ltd for free: we tell you when fair value or trend changes.

China Medical & HealthCare Group Ltd (0383) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of China Medical & HealthCare Group Ltd stock HK$0.58, price HK$0.85, that is 31.4% below the price, quality 34 out of 100. Rating: overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.

6 models, one by oneBear HK$0.5500 to bull HK$0.6100 Growth analysisrevenue history, year by year Quality 34/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · ISIN BMG2133H1016

Thin data Nov 8, 2026

China Medical & HealthCare Group Ltd

0383 · HK

Expensive, weak quality

Our calculation puts a fair price 31% below what the stock costs today.

Low debt

Mixed Growth (revenue 5y +6.2 %/yr in HKD)

Thin margins · 0.5% net margin (TTM)

Costs 90 times its yearly profit.

Fair value HK$0.5800 · Overvalued

Quality 34/100

Negative free cash flow

Trails peers (4/13)

Narrow moat 22/100 · thin data

Thin data

⚠ Small free float

Watch China Medical & HealthCare Group Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range HK$0.6229 – HK$4.71 · fair‑value band HK$0.5500 – HK$0.6100 · the HK$0.8450 price screens above the HK$0.5800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.

Follow China Medical & HealthCare Group in your weekly email

Every Wednesday you see whether China Medical & HealthCare Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tian An Medicare Limited, an investment holding company, primarily operates hospitals in the People's Republic of China and Hong Kong. It operates through Healthcare, Eldercare, Property Development, Property Investment, Financial Services, and Securities Trading and Investments segments.

Show moreShow less

The company is also involved in property development of independent living units and project management of health campus with a focus on eldercare and retirement community including elderly nursing home, service apartments, independent living units and commercial area comprising shopping mall, retail shops, and club hall facilities.

In addition, it develops and sells properties and lands; leases properties; and provides loan financial and healthcare services, as well as trading of securities listed in overseas exchange.

The company was formerly known as China Medical & HealthCare Group Limited and changed its name to Tian An Medicare Limited in April 2024. Tian An Medicare Limited was incorporated in 1989 and is based in Wan Chai, Hong Kong.

The company operates as a subsidiary of Tian An China Investments Company Limited.

Stock analysis

China Medical & HealthCare Group Ltd (0383) currently trades at HK$0.8450, while our model-based Fair Value estimate is HK$0.5800, 31% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Asset-Based group reads highest at a median of HK$1.13 per share, and 2 of the 6 models we run sit above the HK$0.8450 price.

Bear case: the Earnings-Based group reads lowest at HK$0.5800, and 4 of the 6 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$0.5500 (bear) to HK$0.6100 (bull), the price of HK$0.8450 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

China Medical & HealthCare Group Ltd reported revenue of HK$1.6B in FY2026 versus HK$1.5B in FY2022, a compound +2.9%/yr. Reported net income was −HK$26.8M in FY2026.

Key figures

Market cap HK$913M (≈ $116M) Micro · P/E ratio 89.5 · P/S ratio 0.54 · Dividend yield 2.5% · Net margin 0.5% · Return on equity 0.9% · Return on assets (EBIT) 0.6% (5-year average) · Operating margin 6.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 24% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −31%, 0383 screens richer than that median.

Fair Value models

Bear HK$0.5500 Fair Value HK$0.5800 Bull HK$0.6100

Price HK$0.8450 · Downside -31.4%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

EPV HK$0.5500 HK$0.5800 HK$0.6100 74

ROIC Compounder HK$0.5500 HK$0.5800 HK$0.6100 72

EV/EBITDA HK$1.37 HK$1.88 HK$2.39 67

All 6 models by family

Earnings-Based

EPV HK$0.5500 HK$0.5800 HK$0.6100 74

Multiples

EV/EBIT HK$0.5200 HK$0.7400 HK$0.9700 65

EV/EBITDA HK$1.37 HK$1.88 HK$2.39 67

EV/Revenue HK$0.3300 HK$0.5300 HK$0.7400 52

Asset-Based

NCAV (Graham) HK$0.8400 HK$1.13 HK$1.69 54

Economic Profit

ROIC Compounder HK$0.5500 HK$0.5800 HK$0.6100 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 15

How much profit the company makes from its sales and capital

Quality Growth 35

Are margins and returns getting better?

Cashflow 13

Do the profits arrive as real cash?

Financial strength 52

Debt, balance sheet and risk of trouble

Investment 69

Does it invest with discipline instead of growing at any price?

Low Volatility 54

How calm the share price moves, does not count

Price momentum 33

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 18

Distance to the 52-week high, does not count

New shares 42

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+0.7%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+4.4%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+6.2%

Start year 2021 (pandemic). Over 10 years: −3.7% a year

Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−1.9%

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

’26

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−1.1% (2021) → 3.2% (2026)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss

not computed

0383 screens overvalued: fair value 31% below the price. Compare with HCA Healthcare, Inc →

Compare China Medical & HealthCare Group Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks

Beats the industry median on 4/13 measures

Overall it trails its industry peers.

Valuation

Quality Score 34 · Bottom 25%

Fair Value upside −31.4% · Below median

Profitability

Return on equity (12 months) 0.9% · Bottom 25%

Return on assets −0.8% · Bottom 25%

Net margin (12 months) 0.5% · Bottom 25%

Operating margin (12 months) 6.5% · Below median

Growth and dividend

Revenue growth (quarter YoY) 5.6% · Below median

Dividend yield (12 months) 2.5% · Above median

Balance sheet

Debt / equity 0.25× · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 89.5× · Priciest 25%

P/B 0.52× · Cheapest 25%

P/S (12 months) 0.54× · Cheapest 25%

EV/EBITDA 3.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 34

FUTURE (revenue growth)28 · sector 31

PAST (return on equity)4 · sector 32

HEALTH (low debt)88 · sector 90

DIVIDEND (yield)50 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Fresenius Medical Care AG FMS	$23.40	$46.55	+99%	vs 0383
Aier Eye Hospital Group 300015	¥9.01	¥10.88	+21%	vs 0383
DaVita Inc DVA	$191.35	$218.90	+14%	vs 0383
HCA Healthcare, Inc HCA	$494.99	$547.34	+11%	vs 0383
Tenet Healthcare Corporation THC	$283.33	$279.20	−1%	vs 0383
The Ensign Group ENSG	$181.08	$140.09	−23%	vs 0383
Encompass Health Corporation EHC	$137.54	$94.81	−31%	vs 0383
Fresenius SE FRE	€52.48	€34.77	−34%	vs 0383
Apollo Hospitals Enterprise Limited APOLLOHOSP	₹8,446	₹5,234	−38%	vs 0383
Dr. Sulaiman Al Habib Medical Services Group 4013	215.00 SAR	109.45 SAR	−49%	vs 0383

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

China Medical & HealthCare Group Ltd: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/0383?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/0383.HK.svg" width="360" height="84" alt="China Medical &amp; HealthCare Group Ltd: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "China Medical & HealthCare Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/0383

Frequently asked questions

Is China Medical & HealthCare Group Ltd (0383) overvalued or undervalued?

As of Nov 8, 2026, our model estimates a fair value of HK$0.5800 versus a price of HK$0.8450, about 31% lower (overvalued).

What is the fair value of 0383?

Our model-based fair value for China Medical & HealthCare Group Ltd is HK$0.5800 (as of Nov 8, 2026), built from audited fundamentals. The current price: HK$0.8450.

What is the quality score of 0383?

China Medical & HealthCare Group Ltd has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for China Medical & HealthCare Group Ltd (0383)?

Our model-based price target is the fair value of HK$0.5800 (as of Nov 8, 2026) from 6 valuation models. Cautious scenario HK$0.5500, optimistic scenario HK$0.6100. It is a calculation from audited fundamentals, not an analyst target.

What is the China Medical & HealthCare Group Ltd stock forecast for 2026?

Our models put fair value at HK$0.5800, about 31% lower versus a price of HK$0.8450 (overvalued). Cautious scenario HK$0.5500, optimistic scenario HK$0.6100. The calculation is refreshed regularly with new filings.

What is the revenue of China Medical & HealthCare Group Ltd (0383)?

China Medical & HealthCare Group Ltd reported trailing-twelve-month revenue of about HK$1.7B (latest available figure, as of Nov 8, 2026).

Does China Medical & HealthCare Group Ltd pay a dividend?

China Medical & HealthCare Group Ltd currently shows a dividend yield of 2.51% relative to its recent price (as of Nov 8, 2026).

How much is the dividend of China Medical & HealthCare Group Ltd (0383)?

China Medical & HealthCare Group Ltd has a dividend yield of 2.5%.

What is the intrinsic value of China Medical & HealthCare Group Ltd (0383)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Medical & HealthCare Group Ltd it is HK$0.5800 per share (as of Nov 8, 2026), against a price of HK$0.8450. It is the blended result of 6 valuation models in 4 families (Earnings-Based, Multiples, Asset-Based, Economic Profit).

Is China Medical & HealthCare Group Ltd stock overvalued or undervalued in 2026?

As of Nov 8, 2026, 0383 trades above its calculated fair value: price HK$0.8450, fair value HK$0.5800, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 0383?

No. The price is what the market pays today (HK$0.8450); the fair value is what the company's own numbers justify (HK$0.5800). For China Medical & HealthCare Group Ltd the two are HK$0.2650 per share apart. That gap is exactly why we show both numbers side by side.

How much is China Medical & HealthCare Group Ltd worth?

The market values China Medical & HealthCare Group Ltd at about HK$913M (market capitalisation, as of Nov 8, 2026). Per share that is HK$0.8450; our models calculate a fair value of HK$0.5800 per share.

What do the bullish and bearish scenarios say about 0383?

Our models span a range for China Medical & HealthCare Group Ltd: cautious scenario HK$0.5500, base HK$0.5800, optimistic HK$0.6100 per share (as of Nov 8, 2026, price HK$0.8450). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 0383?

China Medical & HealthCare Group Ltd trades at a price-to-earnings ratio of 89.5 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.5800 is built from several models across several years. Other multiples: P/B 0.5, P/S 0.5, EV/EBITDA 3.6.

How solid is the balance sheet of China Medical & HealthCare Group Ltd (0383)?

Balance-sheet figures for China Medical & HealthCare Group Ltd (as of Nov 8, 2026): return on equity 0.9%, debt of 0.25 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.

How far is 0383 from its 52-week high?

China Medical & HealthCare Group Ltd trades at HK$0.8450, about 24% below its 52-week high of HK$1.11 and 8% above the low of HK$0.7800 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.5800 is for.

Which stocks are comparable to China Medical & HealthCare Group Ltd?

From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is China Medical & HealthCare Group Ltd stock attractive at the current price?

The data as of Nov 8, 2026: price HK$0.8450, calculated fair value HK$0.5800 (−31%), Quality Score 34/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 0383 calculated?

We run China Medical & HealthCare Group Ltd through 6 models from 4 families: Earnings-Based, Multiples, Asset-Based, Economic Profit. Every model gets the same audited fundamentals; the fair value of HK$0.5800 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.3% above its aggregate fair value. China Medical & HealthCare Group Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of China Medical & HealthCare Group Ltd (0383)?

The closing price on Nov 6, 2026 was HK$0.8450. Our model-based fair value is HK$0.5800, about 31% lower (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with China Medical & HealthCare Group Ltd right now?

The price sits above even our optimistic bull case (HK$0.6100). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (HK$0.5500 to HK$0.6100), unusually little disagreement for a valuation.

Where does the earnings growth of China Medical & HealthCare Group Ltd (0383) come from?

Earnings per share at China Medical & HealthCare Group Ltd grew −0.2 % a year from 2015 to 2026. Broken into its drivers: revenue per share +40.5 %, EBIT margin −1.5 %, tax rate +0.2 %, residual (interest, one-offs) −28.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of China Medical & HealthCare Group Ltd

How large is the market capitalisation of China Medical & HealthCare Group Ltd (0383)?

The market capitalisation of China Medical & HealthCare Group Ltd is HK$913M (≈ $116M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of China Medical & HealthCare Group Ltd (0383)?

The price-to-sales ratio of China Medical & HealthCare Group Ltd is 0.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What is the dividend yield of China Medical & HealthCare Group Ltd (0383)?

The dividend yield of China Medical & HealthCare Group Ltd is 2.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of China Medical & HealthCare Group Ltd (0383)?

The net margin of China Medical & HealthCare Group Ltd is 0.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of China Medical & HealthCare Group Ltd (0383)?

The return on equity (ROE) of China Medical & HealthCare Group Ltd is 0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of China Medical & HealthCare Group Ltd (0383)?

On an EBIT basis the return on assets of China Medical & HealthCare Group Ltd is 0.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of China Medical & HealthCare Group Ltd (0383)?

The operating margin of China Medical & HealthCare Group Ltd is 6.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at China Medical & HealthCare Group Ltd (0383)?

Revenue at China Medical & HealthCare Group Ltd is growing +5.6% versus a year earlier (3y avg +4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at China Medical & HealthCare Group Ltd (0383)?

Earnings per share at China Medical & HealthCare Group Ltd are growing +300% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does China Medical & HealthCare Group Ltd (0383) generate?

The free cash flow of China Medical & HealthCare Group Ltd is −HK$69.2M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does China Medical & HealthCare Group Ltd (0383) carry?

The net debt of China Medical & HealthCare Group Ltd is HK$149M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch China Medical & HealthCare Group Ltd in the live analysis

One click puts China Medical & HealthCare Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.